durlobactam

Durlobactam is a next-generation, non-beta-lactam beta-lactamase inhibitor of the diazabicyclooctane (DBO) class. It is used in combination with sulbactam to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), particularly those caused by susceptible strains of *Acinetobacter baumannii-calcoaceticus* complex. Durlobactam works by inhibiting class A, C, and D serine beta-lactamases—including OXA-type carbapenemases—thereby protecting sulbactam from enzymatic degradation and restoring its antibacterial activity. The drug was developed using structure-based drug design to optimize reactivity, binding affinity, Gram-negative cell penetration, and intravenous suitability. Durlobactam was first approved in the United States in May 2023 as part of the combination product Xacduro.

Brand names

Xacduro

Other names

durlobactam sodium